DD · 10-Q · 2026Q3

DuPont de Nemours, Inc.

Filed 2026-11-03 · Industrials · View original filing on EDGAR

Everything DD's SEC filings said, ranked

Ranked Events

• Operating Cash Flow TrendsImportance 79 · Surprise 64
  Cash provided by continuing-operations operating activities increased to $1.042 billion in the first nine months of 2026 from $473 million in the comparable 2025 period, an increase of approximately 120%. DuPont…
• Portfolio Reshaping (M&A / Divestiture)Importance 71 · Surprise 60
  DuPont completed the sale of its Aramids business to Arclin on April 1, 2026. Consideration included approximately $1.2 billion in pre-tax cash proceeds, subject to customary adjustments, a $300 million note…
• Aramids DivestitureImportance 59 · Surprise 60
  DuPont completed the sale of its Aramids business to Arclin on April 1, 2026. Consideration included approximately $1.2 billion of pretax cash proceeds, subject to customary adjustments, a $300 million note receivable…
• North Carolina PFAS SettlementImportance 53 · Surprise 60
  On September 9, 2026, DuPont, Chemours, and Corteva/EIDP agreed to settle litigation brought by North Carolina and local governments concerning alleged PFAS-related emissions near the Fayetteville Works site. The…
• NJ PFAS SettlementImportance 53 · Surprise 60
  The court entered the final Judicial Consent Order for the New Jersey settlement on August 7, 2026, with payments due over 25 years; DuPont paid its first annual $71 million installment on September 8, 2026. DuPont and…
• 2026 DuPont Restructuring ProgramImportance 52 · Surprise 42
  DuPont committed to the program in February 2026 to reduce costs, streamline operations and align its organizational structure with strategic priorities. Expected pretax restructuring, asset-related and other…
• Liquidity and Debt PositionImportance 52 · Surprise 46
  At September 30, 2026, DuPont had $1.652 billion in cash and cash equivalents, up from approximately $0.7 billion at December 31, 2025, and $3.094 billion of debt, down from $3.194 billion. The debt reduction primarily…
• Interest Expense TrendsImportance 51 · Surprise 64
  Third-quarter interest expense declined 53% to $40 million from $85 million. Nine-month interest expense fell 52% to $121 million from $252 million. The decrease primarily reflected capital-structure changes following…
• Capital Return ProgramImportance 40 · Surprise 42
  DuPont’s $2 billion share-repurchase authorization supported a $275 million accelerated repurchase in May 2026 and a $250 million accelerated repurchase in August 2026. The company also repurchased approximately $100…
• Income Tax Rate ChangesImportance 40 · Surprise 64
  The effective tax rate on continuing operations was 38.7% in third-quarter 2026, compared with negative 12.1% in third-quarter 2025. For the first nine months, the rate increased to 29.5% from 22.6%. The increase…
• Revenue Performance and MixImportance 37 · Surprise 32
  Third-quarter 2026 net sales increased 4% to $1.868 billion from $1.795 billion, reflecting 5% organic growth and a 1% unfavorable currency impact. Nine-month net sales rose 4% to $5.368 billion from $5.156 billion,…
• Gross Margin DriversImportance 31 · Surprise 32
  Cost of sales was $1.2 billion in both third-quarter 2026 and third-quarter 2025, while cost of sales as a share of net sales declined from 66% to 64%. For the first nine months, cost of sales was $3.5 billion versus…
• Segment ProfitabilityImportance 30 · Surprise 40
  Healthcare & Water Technologies third-quarter Operating EBITDA rose 7% to $263 million from $246 million, driven primarily by organic growth and manufacturing productivity; nine-month EBITDA increased 7% to $765…
• Industrial Market DemandImportance 25 · Surprise 32
  Diversified Industrials organic sales increased 5% in the third quarter and 3% over the first nine months of 2026. Industrial Technologies growth was driven by aerospace market strength in both periods, with electric…
• Healthcare Water DemandImportance 25 · Surprise 32
  Healthcare & Water Technologies organic sales grew 4% in the third quarter and 4% over the first nine months of 2026. Healthcare Technologies growth reflected personal protection and medical packaging in the quarter,…
• Geographic Market CommentaryImportance 17 · Surprise 24
  Building Technologies organic sales growth was led by North America and Asia Pacific in the third quarter, while Asia Pacific led growth over the first nine months of 2026. Healthcare & Water Technologies growth…
• Research and Development ExpenseImportance 17 · Surprise 22
  Third-quarter 2026 R&D expense decreased 19% to $42 million from $52 million, and R&D declined to 2% of sales from 3%. Nine-month R&D expense fell 15% to $131 million from $155 million, with R&D at 2% of sales versus…

Revenue by Product (in millions)

Revenue by Geography (in millions)